RiskReveal
Stage IA-IIA non-squamous Non-Small Cell Lung Cancer (NSCLC), post-resection risk stratification
Key Facts
About Razor Genomics
Razor Genomics, founded in 2009 and based in Nashville, TN, has developed and commercialized the RiskReveal™ molecular stratification test for early-stage, non-squamous NSCLC. The test analyzes a 14-gene signature from tumor tissue to predict recurrence risk, with clinical evidence suggesting it outperforms standard clinicopathological criteria in identifying high-risk patients. By providing a more precise risk assessment, Razor Genomics seeks to address a critical unmet need in the post-surgical management of lung cancer, potentially enabling personalized adjuvant therapy decisions to improve survival rates. The company operates as a commercial-stage diagnostics provider, offering the test through an out-of-network billing model with patient assistance programs.
View full company profile